Bristol Myers Squibb (CELG-RI) Non Operating Income (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has 18 years of Non Operating Income data on file, last reported at -$32.0 million in Q1 2026.

• Non Operating Income for Q1 2026 came in at -$32.0 million, up 90.56% year-over-year; the trailing twelve-month figure through Mar 2026 was -$367.0 million (up 68.11% YoY), and the FY2025 annual result was -$674.0 million, up 24.52% from the prior year.
• Non Operating Income declined to -$32.0 million in Q1 2026 per CELG-RI's latest filing, from $51.0 million in the prior quarter.
• Over five years, Non Operating Income peaked at $413.0 million in Q1 2023 and troughed at -$649.0 million in Q1 2022.
• A 5-year average of -$59.8 million and a median of -$32.0 million in 2026 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2022 and 2023: Non Operating Income plunged 14300.0% in 2022, then surged 163.64% in 2023.
• A 5-year view of Non Operating Income shows it stood at $217.0 million in 2022, then soared by 70.97% to $371.0 million in 2023, then sank by 182.21% to -$305.0 million in 2024, then soared by 116.72% to $51.0 million in 2025, then tumbled by 162.75% to -$32.0 million in 2026.
• Business Quant data shows CELG-RI's Non Operating Income at -$32.0 million in Q1 2026, $51.0 million in Q4 2025, and $108.0 million in Q3 2025.